Cervical cancer is the fourth most common cancer among women globally, with approximately 660,000 new cases and 350,000 deaths reported in 2022  The primary cause is persistent infection with high-risk types of human papillomavirus (HPV), a virus spread through sexual contact. While HPV infections are common, not all lead to cervical cancer. Vaccines are available that protect against high-risk HPV types, and screening programs can detect signs of disease at an early stage, allowing for effective treatment and management. This means that cervical cancer should be one of the most preventable and treatable forms of cancer

In many high-income countries, cervical cancer rates have declined due to widespread screening and vaccination efforts. However, in low- and middle-income countries, where access to these preventive measures is limited, about 90% of new cases and deaths occur  The high incidence and mortality rates in these regions are linked to inadequate access to prevention, diagnosis, and treatment services. For instance, less than 25% of low- and middle-income countries have introduced the HPV vaccine into their national immunization schedules, compared to over 85% of high-income countries.

Early detection through regular screening and vaccination is crucial in preventing cervical cancer. Women are encouraged to undergo routine Pap smears and HPV tests as recommended by healthcare providers. Additionally, the HPV vaccine is recommended for individuals aged 11-12, with catch-up doses available up to age 26. By increasing awareness and access to these preventive measures, the global burden of cervical cancer can be reduced, saving lives and improving women’s health worldwide.